Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 21 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.